182 related articles for article (PubMed ID: 2883132)
1. Effect of a new selective H1 receptor antagonist (levocabastine) in a nasal and conjunctival provocation test.
Pécoud A; Zuber P; Kolly M
Int Arch Allergy Appl Immunol; 1987; 82(3-4):541-3. PubMed ID: 2883132
[TBL] [Abstract][Full Text] [Related]
2. Levocabastine: a new topical approach for the treatment of paediatric allergic rhinoconjunctivitis.
Janssens MM
Rhinol Suppl; 1992 Sep; 13():39-49. PubMed ID: 1358140
[TBL] [Abstract][Full Text] [Related]
3. Comparison of levocabastine, a new selective H1-receptor antagonist, and disodium cromoglycate, in a nasal provocation test with allergen.
Kolly M; Pécoud A
Br J Clin Pharmacol; 1986 Oct; 22(4):389-94. PubMed ID: 2876723
[TBL] [Abstract][Full Text] [Related]
4. Comparison of effects of topical levocabastine and nedocromil sodium on the early response in a conjunctival provocation test with allergen.
Hammann C; Kämmerer R; Gerber M; Spertini F
J Allergy Clin Immunol; 1996 Dec; 98(6 Pt 1):1045-50. PubMed ID: 8977503
[TBL] [Abstract][Full Text] [Related]
5. Topical levocabastine, a selective H1 antagonist, in seasonal allergic rhinoconjunctivitis.
Bende M; Pipkorn U
Allergy; 1987 Oct; 42(7):512-5. PubMed ID: 2891316
[TBL] [Abstract][Full Text] [Related]
6. Effects of topical treatment with H1 and H2 antagonists on clinical symptoms and nasal vascular reactions in patients with allergic rhinitis.
Holmberg K; Pipkorn U; Bake B; Blychert LO
Allergy; 1989 May; 44(4):281-7. PubMed ID: 2567579
[TBL] [Abstract][Full Text] [Related]
7. Levocabastine. An update of its pharmacology, clinical efficacy and tolerability in the topical treatment of allergic rhinitis and conjunctivitis.
Noble S; McTavish D
Drugs; 1995 Dec; 50(6):1032-49. PubMed ID: 8612470
[TBL] [Abstract][Full Text] [Related]
8. Levocabastine: an effective topical treatment of allergic rhinoconjunctivitis.
Janssens MM; Vanden Bussche G
Clin Exp Allergy; 1991 May; 21 Suppl 2():29-36. PubMed ID: 1680536
[TBL] [Abstract][Full Text] [Related]
9. Emedastine ophthalmic solution 0.05% versus levocabastine ophthalmic suspension 0.05% in the treatment of allergic conjunctivitis using the conjunctival allergen challenge model.
Netland PA; Leahy C; Krenzer KL
Am J Ophthalmol; 2000 Dec; 130(6):717-23. PubMed ID: 11124289
[TBL] [Abstract][Full Text] [Related]
10. The effect of levocabastine nasal spray in nasal provocation tests.
Palma-Carlos AG; Palma-Carlos ML; Rombaut N
Int J Clin Pharmacol Res; 1988; 8(1):25-30. PubMed ID: 2896636
[TBL] [Abstract][Full Text] [Related]
11. Topical levocabastine protects better than sodium cromoglycate and placebo in conjunctival provocation tests.
Rimås M; Kjellman NI; Blychert LO; Björkstén B
Allergy; 1990 Jan; 45(1):18-21. PubMed ID: 1968726
[TBL] [Abstract][Full Text] [Related]
12. Effect of levocabastine, a new H1 antagonist, in a conjunctival provocation test with allergens.
Zuber P; Pécoud A
J Allergy Clin Immunol; 1988 Oct; 82(4):590-4. PubMed ID: 2902114
[TBL] [Abstract][Full Text] [Related]
13. Eosinophil cationic protein (ECP) and tryptase in the nasal lavage fluid (NLF) of children with grass pollen rhinitis: levocabastine effect.
Bernardini R; Novembre E; Mugnaini L; Rossi ME; Vierucci A
Allergy Asthma Proc; 1998; 19(2):75-80. PubMed ID: 9578915
[TBL] [Abstract][Full Text] [Related]
14. Effects of topical budesonide and levocabastine on nasal symptoms and plasma exudation responses in seasonal allergic rhinitis.
Svensson C; Andersson M; Greiff L; Blychert LO; Persson CG
Allergy; 1998 Apr; 53(4):367-74. PubMed ID: 9574878
[TBL] [Abstract][Full Text] [Related]
15. Levocabastine. A review of its pharmacological properties and therapeutic potential as a topical antihistamine in allergic rhinitis and conjunctivitis.
Dechant KL; Goa KL
Drugs; 1991 Feb; 41(2):202-24. PubMed ID: 1709851
[TBL] [Abstract][Full Text] [Related]
16. Topical levocabastine compared with orally administered terfenadine for the prophylaxis and treatment of seasonal rhinoconjunctivitis.
Søhoel P; Freng BA; Kramer J; Poppe S; Rebo R; Korsrud FR; Garud O; Woxen OJ; Olsen AK
J Allergy Clin Immunol; 1993 Jul; 92(1 Pt 1):73-81. PubMed ID: 8101534
[TBL] [Abstract][Full Text] [Related]
17. Comparative efficacy of olopatadine 0.1% ophthalmic solution versus levocabastine 0.05% ophthalmic suspension using the conjunctival allergen challenge model.
Abelson MB; Greiner JV
Curr Med Res Opin; 2004 Dec; 20(12):1953-8. PubMed ID: 15701212
[TBL] [Abstract][Full Text] [Related]
18. Intranasal levocabastine provides fast and effective protection from nasal allergen challenge.
Bachert C; Wagenmann M; Vossen-Holzenkamp S
Rhinology; 1996 Sep; 34(3):140-3. PubMed ID: 8938880
[TBL] [Abstract][Full Text] [Related]
19. A double-blind, placebo-controlled comparison of treatment with fluticasone propionate and levocabastine in patients with seasonal allergic rhinitis. FLNCO2 Italian Study Group.
Ortolani C; Foresi A; Di Lorenzo G; Bagnato G; Bonifazi F; Crimi N; Emmi L; Prandini M; Senna GE; Tursi A; Mirone C; Leone C; Fina P; Testi R
Allergy; 1999 Nov; 54(11):1173-80. PubMed ID: 10604553
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of levocabastine in conjunctival provocation studies.
Janssens M
Doc Ophthalmol; 1992; 82(4):341-51. PubMed ID: 1363980
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
